{"prompt": "['Novartis', 'Confidential', 'Page 63', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '7.7', 'Idiosyncratic drug reactions monitoring', 'IDRs are adverse drug reactions that do not occur in most patients (i.e., they are rare,', 'occurring 1 in 10,000 to 1 in 100,000 patients) and do not result from known pharmacological', 'effects of a drug. Their onset is unpredictable and they may involve one or more organ', 'systems, most notably the immune system, liver and blood cells.', 'The investigator should pay special attention to any adverse events which may be a potential', 'IDR reported by a patient. If such an event occurs, the investigator should report the event as', 'per standard adverse event reporting procedures (i.e., serious adverse events for those meeting', 'serious criteria and non-serious adverse events for those meeting non-serious adverse event', 'criteria as defined in the protocol).', 'The investigator may be also be contacted by Novartis regarding AEs that may resemble an', 'IDR. A list of terms considered IDRs are provided in Appendix 4.', 'Events with potential to be IDRs will be identified thorough a pre-specified search algorithm', 'based on the standardized medical dictionary for regulatory activities (MedDRA) Queries as', 'described in the study analysis plan. These events will be reviewed by the DMC on a regular', 'basis.', '8', 'Data review and database management', '8.1', 'Site monitoring', \"Before study initiation, at a site initiation visit or at an investigator's meeting, a Novartis\", 'representative will review the protocol and data capture requirements (i.e. eSource or eCRFs)', 'with the investigators and their staff. During the study, Novartis employs several methods of', 'ensuring protocol and good clinical practice (GCP) compliance and the quality/integrity of the', \"sites' data. The field monitor will visit the site to check the completeness of patient records,\", 'the accuracy of data capture / data entry, the adherence to the protocol and to Good Clinical', 'Practice, the progress of enrollment, and to ensure that study treatment is being stored,', 'dispensed, and accounted for according to specifications. Key study personnel must be', 'available to assist the field monitor during these visits. Continuous remote monitoring of each', \"site's data may be performed by a centralized Novartis CRA organization. Additionally, a\", 'central analytics organization may analyze data and identify risks and trends for site', 'operational parameters, and provide reports to Novartis Clinical Teams to assist with trial', 'oversight.', 'The investigator must maintain source documents for each patient in the study, consisting of', 'case and visit notes (hospital or clinic medical records) containing demographic and medical', 'information, laboratory data, electrocardiograms, and the results of any other tests or', 'assessments. All information on CRFs must be traceable to these source documents in the', \"patient's file. The investigator must also keep the original informed consent form signed by\", 'the patient (a signed copy is given to the patient).', 'The investigator must give the monitor access to all relevant source documents to confirm', 'their consistency with the data capture and/or data entry. Novartis monitoring standards', 'require full verification for the presence of informed consent, adherence to the']['Novartis', 'Confidential', 'Page 64', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all', 'primary variables. Additional checks of the consistency of the source data with the CRFs are', 'performed according to the study-specific monitoring plan. No information in source', 'documents about the identity of the patients will be disclosed.', '8.2', 'Data collection', 'Designated investigator staff will enter the data required by the protocol into the Oracle', 'Clinical/Remote Data Capture (OC/RDC) system. Designated investigator site staff will not', 'be given access to the system until they have been trained.', 'Automatic validation procedures within the system check for data discrepancies during and', 'after data entry and, by generating appropriate error messages, allow the data to be confirmed', 'or corrected online by the designated investigator site staff. The Investigator must certify that', 'the data entered into the electronic Case Report Forms are complete and accurate. After', 'database lock, the investigator will receive copies of the patient data for archiving at the', 'investigational site.', '8.3', 'Database management and quality control', 'Novartis staff (or contract research organization (CRO) working on behalf of Novartis) review', 'the data entered into the CRFs by investigational staff for completeness and accuracy and', 'instruct the site personnel to make any required corrections or additions. Queries are sent to', 'the investigational site using an electronic data query. Designated investigator site staff is', 'required to respond to the query and confirm or correct the data.', 'Concomitant medications entered into the database will be coded using the WHO Drug', 'Reference List, which employs the anatomical therapeutic chemical (ATC) classification', 'system. Concomitant procedures, non-drug therapies and adverse events will be coded using', 'the medical dictionary for regulatory activities (MedDRA) terminology.', 'Laboratory samples will be processed centrally and the results will be sent electronically to', 'Novartis (or a designated CRO).', 'Spirometry and ECG readings will be processed centrally and the results will be sent', 'electronically to Novartis (or a designated CRO).', 'Diary data will be entered into an electronic diary by the patient and patients will fill in their', 'PRO data in a site-based tablet. The system will be supplied by a vendor(s), who will also', 'manage the database. The database will be sent electronically to Novartis personnel (or', 'designated CRO).', 'Randomization codes and data about all study drug(s) dispensed to the patient and all dosage', 'changes will be tracked using an Interactive Response Technology (IRT). The system will be', 'supplied by a vendor, who will also manage the database. The database will be sent', 'electronically to Novartis (or a designated CRO).', 'Each occurrence of a code break via IRT will be reported to the clinical team and monitor.', 'The code break functionality will remain available until study shut down or upon request of', 'Novartis.']\n\n###\n\n", "completion": "END"}